# Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.

> **NCT02001857** · PHASE4 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 200 (actual)

## Conditions studied

- Prostate or Bladder Cancer

## Interventions

- **DRUG:** 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.

## Key facts

- **NCT ID:** NCT02001857
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2017-02
- **Final completion:** 2017-08
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2017-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02001857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02001857, "Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02001857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*